



HAL
open science

Prevalence and association of Human Parvovirus B19V with Hepatitis B and C viruses in Nigeria

Oluyinka Olaadele Opaleye, Ademola Hezekiah Fagbami, Albert Lalremruata,
Jurgen F Kun

► **To cite this version:**

Oluyinka Olaadele Opaleye, Ademola Hezekiah Fagbami, Albert Lalremruata, Jurgen F Kun. Prevalence and association of Human Parvovirus B19V with Hepatitis B and C viruses in Nigeria. *Journal of Medical Virology*, 2011, 83 (4), pp.710. 10.1002/jmv.22008 . hal-00614672

HAL Id: hal-00614672

<https://hal.science/hal-00614672>

Submitted on 15 Aug 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Prevalence and association of Human Parvovirus B19V with Hepatitis B and C viruses in Nigeria

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-1859.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	28-Oct-2010
Complete List of Authors:	Opaleye, Oluyinka; Institute for Tropical Medicine, Host parasite interaction Fagbami, Ademola; Ladoke Akintola University of Technology, Medical Microbiology and Parasitology Lalremruata, Albert; Institute for Tropical Medicine, Host Parasite Interaction Kun, Jorgen; Institute for Tropical Medicine, Host parasite interaction
Keywords:	hepatitis B virus, hepatitis C virus, human parvovirus B19, liver disease, genotype

SCHOLARONE™
Manuscripts

Tables 1: Comparison of subgroups of patients and controls

	HBV infected n=76	HBV HCV co infected n=17	Non HBV/HCV n=44
Mean Age	35.4	31.5	35.5
Gender (M/F)	48/28	13/4	19/25
IgM positives	24 (32%)	6 (35%)	14 (32%)
IgG positives	25 (33%)	8 (47%)	12 (27%)
B19V DNA positives	8 (11%)	3 (18%)	4 (9%)
HBV DNA positives	47 (62%)	10 (59%)	0 (0%)

Table 2: Parvovirus B19V serological and DNA status in HBV infected individuals

	IgG(-) IgM (-)	IgG (+) IgM (-)	IgG(+) IgM(+)	IgG(-) IgM (+)
B19V DNA +ves n=8	2 (25%)	1 (13%)	1 (13%)	4 (50%)
B19V DNA -ves n=68	35 (51%)	14 (21%)	9 (13%)	10 (15%)

Table 3: Parvovirus B19V serological and DNA status in HBV HCV co-infected individuals

	IgG(-) IgM (-)	IgG (+) IgM (-)	IgG(+) IgM(+)	IgG(-) IgM (+)
B19V DNA +ves n=3	1 (33%)	0 (0%)	1 (33%)	1 (33%)
B19V DNA -ves n=14	6 (43%)	4 (29%)	3 (21%)	1 (7%)

Table 4: Characteristic of HBV infected patients segregated according to clinical presentation

Characteristics	Symptomatic HBV patients	Asymptomatic HBV carriers
Mean Age (yrs)	35.5	35.4
Gender (M/F)	11/9	37/19
HBsAg positive	20 (100%)	56 (100%)
Anti HCV positive	3 (15%)	14 (25%)
HBV DNA positive	11 (55%)	36 (64%)
B19V DNA positive	4 (20%)	4 (7%)
B19V IgG positive	4 (20%)	18 (32%)
B19V IgM positive	7 (35%)	17 (30%)

Table 5: Genotype distribution of identified parvovirus B19V isolates

Sample No	Age (yrs)	Sex	Anti HCV	HBsAg	Genotype
NGA 125	21	F	Neg	Neg	1B
NGA 507	24	F	Neg	Pos	1A
NGA 218	30	M	Neg	Pos	1B
NGA 149	26	M	Pos	Pos	1A
NGA 572	43	F	Neg	Pos	1B
NGA 84	58	F	Neg	Neg	1A
NGA 331	20	M	Neg	Pos	3B
NGA 373	26	M	Neg	Neg	1B
NGA 160	44	F	Neg	Neg	1B
NGA 177	36	M	Pos	Pos	1A
NGA 167	42	F	Pos	Pos	1B
NGA 668	31	M	Neg	Pos	3B




FIG. 1. Phylogenetic tree constructed from partial parvovirus B19 NS1/VP1u region. Twelve B19-positive samples from Nigeria [NGA 668, NGA167, NGA 177, NGA 160, NGA373, NGA 331, NGA84, NGA572, NGA149, NGA218, NGA507 and NGA125] were aligned with comparative reference sequences identified by their GenBank accession numbers : Genotype 1, AB030694, AF113323, AF162273, M13178, DQ225148, DQ225149, DQ225150, DQ225151, DQ357064 and DQ357065; Genotype 2, AY064476, AY044266, AY661663 and AY661664; Genotype 3, AX003421 and AY083234]. The phylogenetic tree of a distance matrix [Kimura two parameter method] was created using the neighbor- joining method bootstrap 1000 replicate. Bar, 0.01 nucleotide substitutions per site.

Fig 2a. Nucleotide sequence alignment of 12 Nigerian B19 isolates and 16 reference sequence identifiable by their accession number.

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AF162273 : .....
DQ225151 : .....
DQ225148 : .....
NGA507 : .....G.....
DQ225150 : .....G.....
NGA177 : .....G.....
NGA84 : .....G.....
NGA149 : .....G.....
DQ225149 : .....G.....
AB030694 : .....C.....
AF113323 : .....
NGA373 : .....
NGA167 : .....
NGA125 : .....
NGA572 : .....
NGA160 : .....
NGA218 : .....A.....
M13178 : .....G.....
DQ357064 : .....C.....A.....T.....C.....G.....G
DQ357065 : .....C.....A.....T.....C.....G.....G
AY064476 : ..G...T...C...A...G...T...G...A...C...T...T...G...A...G
AY661664 : ..G...T...G...T...G...A...C...T...T...G...A...G
AY044266 : ..G...T...G...T...G...A...C...T...T...G...A...G
AY661663 : ..G...T...G...T...G...A...C...T...T...G...A...G
NGA331 : ..G...T...G...T...C...G...G...TT...T...G...A...
NGA668 : ..G...T...G...T...C...G...G...TT...T...G...A...
AY083234 : ..G...T...G...T...C...G...G...T...T...G...A...
AX003421 : ..G...T...C...G...A...C...G...G...C...T...T...G...A...

AF162273 : .....
DQ225151 : .....
DQ225148 : .....
NGA507 : .....
DQ225150 : .....
NGA177 : .....
NGA84 : .....
NGA149 : .....C.....
DQ225149 : .....
AB030694 : .....
AF113323 : .....T.....
NGA373 : .....T.....
NGA167 : .....T.....
NGA125 : .....T.....
NGA572 : .....T.....C.....
NGA160 : .....T.....C.....
NGA218 : .....T.....
M13178 : .....
DQ357064 : .....T.....T.....
DQ357065 : .....T.....T.....
AY064476 : .....T.....T.....A...G...T...G...
AY661664 : .....T.....T.....
AY044266 : .....T.....T.....G...
AY661663 : .....T.....T.....
NGA331 : ..C...C...A...T...T...T...G...A...
NGA668 : ..C...C...A...T...T...T...G...A...
AY083234 : ..C...A...T...T...T...G...A...
AX003421 : ..C...A...T...T...T...A...T...

```

Fig 2b. Alignment of the translated amino acid sequence of NS1 region of 12 Nigerian B19 isolates and 16 reference sequences identifiable by their accession number.

Accession Number	LPVCCVQHIN	NSGGGLGLCP	HCINVGAWYN	GWKFREFTPD	LVRCSCHVGA	SNPFSVLTK	KCAYLSGLQS	FVDYE
AY064476	LPVCCVQHIN	NSGGGLGLCP	HCINVGAWYN	GWKFREFTPD	LVRCSCHVGA	SNPFSVLTK	KCAYLSGLQS	FVDYE
AY044266
AY661663
AY661664
DQ357064
DQ357065
NGA373
NGA167
NGA125
NGA572P.....
NGA160
NGA218S.....
AF113323
M13178
AF162273
DQ225151
DQ225148
NGA177
NGA84
Q225150
NGA507
NGA149H.....
DQ225149H.....
AB030694
NGA331E.....S.....Y.....
NGA668E.....Y.....
AY083234E.....
AX003421E.....

1
2
3
4 **Prevalence and association of Human Parvovirus B19V with Hepatitis**
5 **B and C viruses in Nigeria**
6
7
8
9

10
11 Opaleye O.O^{1,2}, Fagbami A.H², Lalremruata A¹, Kun J.F. J^{1*}
12
13
14
15
16
17
18
19

20 ¹Institute for Tropical Medicine, University Tübingen, Germany
21

22 ²Department of Medical Microbiology and Parasitology Ladoke Akintola University of
23 Technology. Nigeria
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 ***Corresponding Author: Prof JFJ Kun**
43

44 **Institute for Tropical Medicine,**
45

46 **University Tübingen, Wilhelmstrasse 27,**
47

48 **72074 Tübingen Germany**
49

50 **Tel. +49-7071-2982191; Fax: +49-7071-294684;**
51

52 **E-mail: juergen.kun@uni-tuebingen.de**
53
54
55
56
57
58
59
60

Abstract

Co-infection of parvovirus B19 with hepatitis B virus has been found in patients with acute and chronic hepatitis. The clinical significance of parvovirus B19 in hepatitis B co-infected patients is still controversial. In this study parvovirus B19 antibodies and DNA were investigated in serum samples from 76 patients with HBV infection, 17 with HBV/ HCV co-infection and 44 healthy controls. In the sera from patients with HBV infection, anti-B19V IgM and IgG antibodies were detected in 24/76 (32%) and 25/76 (33%), in 6/17 (35%) and 8/17 (47%) of HBV/HCV co-infected patients, and in 14/44 (32%) and 12/44 (12%) of a non-hepatitis healthy controls respectively. B19V DNA was detected in 8/76 (11%) of patients with HBV infection and in 3/17 (18%) of patients with a HBV/HCV co-infection, and in 4/44 (9%) healthy controls. The occurrence of parvovirus B19 DNA was significantly higher in patients with symptomatic HBV 4/20 (20%) compared to asymptomatic HBV carrier 4/56 (7%) ($p < 0.05$). Ten of the positive B19V DNA sequences belonged to B19V genotype 1 while two belonged to genotype 3. The results of this study showed a significant difference in the prevalence of parvovirus B19 DNA in symptomatic HBsAg-positive as compared to asymptomatic HBsAg positive individuals, however the conclusion that parvovirus B19 infection increased the frequency of liver disease was not supported. Long-term longitudinal studies are, however, required to determine the synergistic effect of parvovirus B19 infection in HBV or HBV and HCV co-infected persons.

INTRODUCTION

Human parvovirus B19 infection is common worldwide and epidemics occur across the Americas, Europe and Asia[Young and Brown 2004]. The virus is transmitted effectively by close contact or blood transfusion. The prevalence of specific IgG antibodies against B19V increases with advancing age: while it is about 15% in children, it increases to approximately 30 to 60% in adults and it exceeds 85% in the elderly population[Henriques et al., 2005].

Human parvovirus B19 is a member of the erythroviruses within the parvoviridae family. It is a small, non-enveloped virus containing a single-stranded DNA of 5600 nucleotides and composed of two capsid proteins, VP1 (84kDa) and VP2 (58kDa), and a non-structural protein, NS1 (77kDa). The two capsid proteins have the same open reading frame and VP1 is identical to VP2 except for an additional 227 amino acids at the NH₂-terminus. Over 95% of capsid proteins are VP2, while VP1 accounts for less than 5%. These B19V structural proteins are known to determine the virus tropism and elicit neutralizing antibody responses [Agbandje et al., 1995; Brown et al., 1991; Cotmore et al., 1986]. These neutralizing antibodies are directed at epitopes from both VP2 and the unique region of VP1. Recently, several strains with considerable sequence diversity were discovered, resulting in the identification of three distinct genetic clusters; genotypes 1,2 and 3 are responsible for the majority of human infections worldwide [Servant-Delmas et al., 2009a; Servant-Delmas et al., 2009b].

During the course of B19V infection, a high-titer viremia can appear and last approximately 6–8 days; the viral titer then decreases and viral DNA is detectable for several months by polymerase chain reaction (PCR). Specific IgM antibodies can be determined in parallel to the onset of symptoms (12–17 days after exposure) and decrease between 30 and 60 days later.

1
2
3 Moreover, IgG antibodies appear several days after IgM and remain for several years indicating
4
5
6 past infection [Grossebley et al., 1994; Nishida et al., 1997].
7

8
9 Human parvovirus B19 has been associated with a variety of clinical manifestations including
10
11 erythema infectiosum, hydrops fetalis, aplastic anemia, thrombocytopenia, leukopenia,
12
13 myocarditis, arthritis, and vasculitis [Bizjak et al., 2009; Booth et al., 2010; Buyukkose et al.,
14
15 2009]. Recently, hepatic involvement has also been reported in patients with parvovirus B19
16
17 infection, especially in patients with fulminant hepatitis or acute hepatitis although the role of
18
19 this virus as a possible pathogen causing fulminant, chronic or acute hepatitis is still
20
21 controversial [Hsu et al., 2005; Toan et al., 2006; Wong et al., 2003]. However it is known that
22
23 the cellular receptor of B19V is the P antigen located on the hepatocytes [Schneider et al.,
24
25 2008; Soderlund et al., 1997]. Therefore, the virus may play a role in aggravating the liver
26
27 disease resulting from hepatitis B and C virus infection as reported previously [Hsu et al., 2005].
28
29
30
31
32
33 In Nigeria HBV and HCV infection are endemic with a seroprevalence of approximately 13%-
34
35 16% and 3%- 5% respectively [Imarengiaye et al., 2006; Mabayoje et al., 2007; Opaleye et al.,
36
37 2010; Uneke et al., 2005], however the seroprevalence of parvovirus B19 in the general
38
39 population is yet unknown. Data on parvovirus B19 in Nigeria is limited to one recent study, in
40
41 which five isolates of B19V DNA were found from patients with rash or fever and negative for
42
43 both measles and rubella in Nigeria and characterized [Hubschen et al., 2009].
44
45
46
47

48
49 The aim of the present study was to investigate the association of parvovirus B19 infection in
50
51 people with hepatitis B or C infection as compared to persons without hepatitis B or C, as well
52
53 as symptomatic hepatitis B patients as compared to asymptomatic HBV carriers in Nigeria.
54

55 56 **METHOD** 57 58 59 60

Study subjects

Serum samples were collected from patients diagnosed with hepatitis with clinical symptoms and healthy blood donors. In total, 20 samples were collected from symptomatic persons infected with HBV and 56 from asymptomatic hepatitis B carrier while 44 persons negative for HBV and HCV were recruited as controls. Approximately 5ml of blood was drawn intravenously from each individual after informed consent. The study was approved by the ethical committee of Ladoke Akintola University of Technology Teaching Hospital, Osun, Nigeria.

Detection of HBsAg and anti-HCV antibody

Sera were tested for HBsAg and Anti-HCV using a third-generation enzyme-linked immunosorbent assay [ELISA] (Human diagnostics, Wiesbaden, Germany). All tests were performed following manufacturer's instructions.

Detection of anti-B19V antibodies.

Antibodies to human parvovirus B19 were detected by using parvovirus B19 IgM and IgG enzyme immunoassay Kits (Parvovirus B19 IgG and IgM, DxSelect™ FOCUS Diagnostic, Germany). These assays use a recombinant VP1 protein to capture IgG and IgM. Both assays were performed and interpreted according to the manufacturer's instructions.

DNA purification and polymerase chain reaction amplification for parvovirus B19

DNA was extracted from all serum samples using a QIA Amp blood kit (QIAGEN, Hilden, Germany) as directed by the manufacturer. The detection of B19V DNA was done by nested PCR (nPCR) using primers specific for the VP1/VP2 coding sequence has been described previously [Bultmann et al., 2003]. All samples testing positive for B19V were confirmed with a second PCR, which was different from the first PCR in order to exclude contamination, using

1
2
3 B19V primers (P5F and P5R for the first PCR and n-P5F and n-P5R for the nPCR) specific for the
4 subgenomic NS1/VP1u region from nt 2355 to 2690 (numbering according to GenBank
5
6 accession no. AF162273) as previously described [Toan et al., 2006]. The PCR conditions used
7
8 for the first PCR consist of a 35 cycles of 94°C for 30s, 48°C for 30s and 72°C for 45s and a 40
9
10 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 45 s was used for the nPCR.
11
12
13
14
15

16 **Polymerase chain reaction amplification for HBV**

17
18 The presence of HBV DNA was examined in all samples using a diagnostic PCR approach. Primer
19
20 pairs designed from the highly conserved regions of the S-gene of the HBV was utilized. A nPCR
21
22 was also performed for all 120 individuals: First using an outer primer pair HBPr134 (sense) 5'-
23
24 TGCTGCTATGCCTCATCTTC - 3' and HBPr135 (antisense) 5'- CAGAGACAAAAGAAAATTGG – 3'
25
26 genomic DNA was amplified. PCR amplifications were carried out in 25 µl reaction volumes with
27
28 5 ng of genomic DNA, 10x PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl; Qiagen), 2 mM of
29
30 dNTPs, 50ng of each primer and 1 U Ampli Taq gold DNA polymerase (Applied Biosystems) on a
31
32 PTC 200 (Peltier Thermal cycler). Thermal cycling parameters were: initial denaturation at 94 °C
33
34 for 2 min, followed by 35 cycles of 30sec at 94 °C denaturation, 30 sec at 52 °C annealing
35
36 temperature, 45 sec at 72 °C extension, followed by a final extension of 5 min at 72 °C.
37
38 Subsequent PCR was performed with an inner primer pairs HBPr75 (sense) 5' –
39
40 CAAGGTTATGTTGCCCGTTTGTCC - 3' and HBPr94 (antisense) 5'- GGTATAAAGGGACTCACGATG-
41
42 3'. Thermal cycling parameters remained the same as mentioned above except for the number
43
44 of cycles that is increased to 40 cycles of amplification. Each PCR product (5 µl) was analysed by
45
46 electrophoresis in 2% agarose gels. A positive control (HBV plasmid DNA) and negative controls
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were integrated to each of these runs to validate the PCR products that yielded a 340bp
4
5 fragment.
6
7

8 9 **Sequencing and phylogenetic analysis of parvovirus B19**

10
11
12 The B19V DNA positive samples were sequenced after using EXO-SAP-IT (exonuclease I and
13
14 stream alkaline phosphatase enzyme, USB, Cleveland, OH, USA), by incubating 5ul of the PCR
15
16 product with the 2ul of the enzyme at 37°C for 15min then at 85°C for 15min. The PCR products
17
18 were sequenced twice using the forward and reverse primers (nP5R and nP5F), for sequencing
19
20 of a fragment of the NS1/VP1u region from nt 2355 to 2690 (numbering according to GenBank
21
22 accession no. AF162273). The sequencing was done using dye labeled dideoxy terminators (Big
23
24 Dye, Applied Biosystems, Foster city, USA) BD and analysed on a ABI PRISM Genetic analyzer
25
26 3100 (Applied Biosystems).
27
28
29
30
31

32 **B19V genotype analysis**

33
34 B19V sequences were aligned by using CLUSTAL_W [Thompson et al., 1994] and BLAST
35
36 (National Center for Biotechnology Information; <http://www.ncbi.nlm.nih.gov/blast/blast.cgi>).
37
38 The reliability of alignment was additionally checked by using the BioEdit program (Department
39
40 of Microbiology, North Carolina State University, Raleigh, NC, USA;
41
42 <http://www.mbio.ncsu.edu/BioEdit/bioedit.html>). Phylogenetic and molecular evolutionary
43
44 analyses were conducted by the neighbour-joining method using *MEGA* version 4 [Tamura et
45
46 al., 2007]. Prototype B19V sequences from the GenBank were used as reference sequences
47
48 (GenBank accession numbers were as follows: genotype 1, AB030694,AF113323, AF162273,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 M13178, DQ225148, DQ225149, DQ225150, DQ225151, DQ357064 and DQ357065; genotype
4
5 2, AY064476, AY044266, AY661663 and AY661664; genotype 3, AX003421 and AY083234).

8 **Statistical analysis.**

9
10 Statistical analysis was performed by using the SPSS software (Chicago IL version 15.0).

11
12
13 Categorical variables were compared using Fishers exact test.
14
15
16
17

18 **RESULTS**

19 **PCR and ELISA analysis for the presence of B19V DNA and antibodies in patient samples**

20
21 In order to determine the presence of B19V DNA in peripheral blood samples of 120 Nigerians,
22
23 nPCR was used for amplifying B19V amplicons from the coding VP1/VP2 and confirmed by a
24
25 second PCR coding NS1/VP1u regions. The results indicated that B19V genomes were identified
26
27 in 8 of 76 (11%) patients infected with HBV and 4 of 44 (9%) individuals in the control group.
28
29

30
31 Serum samples taken from the same patients were also tested for IgM and IgG of B19V
32
33 antibodies. Anti-B19V IgM and IgG antibodies were detected in 24 (32%) and 25 (33%) of 76
34
35 samples from patients with HBV infection, 6 (35%) and 8 (47%) of 17 serum samples from
36
37 patients with HBV/ HCV co-infection, respectively. The presence of B19V IgM and IgG
38
39 antibodies was detected in 32% and 27%, respectively, among the 44 controls (Table 1).
40
41
42
43
44

45
46 The frequency of anti-B19V IgG(-)IgM(+) was 50% in B19V DNA positive individuals co-infected
47
48 with HBV, while it was 15% in B19V DNA negative individuals indicating recent infection and a
49
50 higher level of viremia in individuals with detectable B19V DNA (Table 2). The occurrence of
51
52 parvovirus B19 DNA was significantly higher in patients with symptomatic HBV 4/20 (20%)
53
54 compared to asymptomatic HBV carrier 4/56 (7%) ($p < 0.05$) (Table 4).
55
56
57
58
59
60

Nucleotide sequence and phylogenetic analysis

Twelve B19V sequences of the NS1/VP1u region from this study and 16 reference sequences from the GenBank were analysed using the phylogenetic tree method. From this analysis, 10 of the Nigerian samples clustered with B19V genotypes 1 while two clustered with genotype 3. Particularly, 4 samples clustered with genotype 1A while 6 clustered with genotype 1B and the remaining 2 of the Nigerian isolates clustered with genotype 3B (Fig 1). Interestingly 6 sequences from the Nigerian isolates clustered in a different branch within the genotype 1A with a strong bootstrap of 83 at 1000 bootstrap replicate along with a reference sequence GenBank accession number M13178 while the other 4 clustered with the reference sequence with GenBank accession numbers AB030694, AF113323, AF162273, DQ225148, DQ225149, DQ225150 and DQ225151 (Fig 1).

Nucleotide and amino acid divergence in the Nigerian Isolates

The mean genetic distance among the genotype 1 sequence in this study within the 252nt region sequenced was 3% and the maximum genetic distance was 5% between reference sequence DQ357064, DQ357065 and the samples NGA218, NGA373, NGA125, NGA167, NGA160 and NGA572. From the Nigerian isolates some unique nucleotide and amino acid divergences when compared with the 16 reference sequence using pairwise analyses of nucleotide sequences coding for the NS1/VP1 region were identified. In sample NGA149 there was a G to C change at position 2619, there was G2445A in NGA218, A2631G in NGA668, T2449C and A2631G in NGA 331 which translate to an amino acid substitution of W817R and

1
2
3 L852P in this sample NGA331. An L864P mutation was seen in NGA160, C866R in NGA572 and
4
5
6 L852P mutation in NGA668 (Fig 2a and 2b). The sequences data from the B19V isolates in this
7
8
9 study have been submitted to the gene bank, their accession number is HM030967-HM030987.

10 11 12 13 **DISCUSSION**

14
15
16 This study showed that B19V is common in the Nigerian population although the prevalence is
17
18 low as compare to that in Vietnam and Taiwan in hepatitis B virus infected persons [Hsu et al.,
19
20 2005; Toan et al., 2006]. It was also found that the prevalence of B19V infection in HBV-infected
21
22 patients was not significantly higher than that in the healthy control. However, in patients with
23
24 symptomatic HBV infection as well as those co-infected with HBV and HCV, the B19V
25
26 prevalence was significantly higher. In this study, the presence of B19V in the healthy
27
28 population supports the finding in a study where B19VDNA was isolated from the bone marrow
29
30 of 4/45 [9%] of healthy persons [Cassinotti et al., 1998].
31
32
33
34
35

36 This study also revealed that B19V DNA is found more often in symptomatic Persons infected
37
38 with HBV when compared with asymptomatic HBV individuals, suggesting that the virus might
39
40 play a synergistic role in liver disease outcome in those co-infected with HBV, supporting a
41
42 previous finding from Vietnam [Toan et al., 2006].
43
44
45

46 Previous studies have suggested that B19V may have a potential role in the pathogenesis of
47
48 liver disease including fulminant liver failure [Arista et al., 2003; Bernuau et al., 1999b; Karetnyi
49
50 et al., 1999; Langnas et al., 1995] and post transplantation liver dysfunction [Lee et al., 2002].
51
52

53 This concept has been supported by the detection of B19V DNA in the liver of patients with
54
55 hepatitis [Bernuau et al., 1999; Drago et al., 1999; Hillingso et al., 1998; Karetnyi et al., 1999;
56
57
58
59
60

1
2
3 Yoto et al., 1996]. It has been shown also that there is a significant association between
4
5
6 HBV/B19V co-infection and HBV associated hepatocellular carcinoma in adults [Toan et al.,
7
8
9 2006].

10
11 Published data on parvovirus genotypes in Nigeria is very limited. A study reported the
12
13 presence of B19V genotypes 1 and 3 from 5 isolates from Nigerian, mostly from rash/fever
14
15 patients who were negative for both measles and rubella [Hubschen et al., 2009]. In our study
16
17 the phylogenetic analysis revealed a similar result with HBV infected patients suggesting that
18
19 the dominating genotype of B19V in Nigeria is genotype 1.
20
21

22
23 Another interesting finding of the phylogenetic analysis is that the B19V sequences from the
24
25 Nigerian isolates are more diverse within genotype 1 as they clustered in two different
26
27 branches within the genotype 1A earlier designated by a study on Vietnamese isolates [Toan et
28
29 al., 2006]. However further studies on the whole B19V genome would be necessary to unravel
30
31 the full genetic diversity of the Nigerian B19V isolates.
32
33

34
35 In conclusion, this study has shown that human parvovirus B19 is associated with symptomatic
36
37 HBV infection, however, the mechanism of its synergistic effect on symptomatic HBV infection
38
39 needs to be investigated further.
40
41
42
43
44

45 46 **Acknowledgments**

47
48 We wish to acknowledge the support from Deutscher Akademischer Austausch Dienst [DAAD]
49
50 and Ladoke Akintola University of Technology [Lautech] Ogbomoso, Oyo State, Nigeria. We are
51
52 also thankful for the excellent technical assistance by Anthony Ajua, Andrea Weierich, Viola
53
54 Galinat and Velia Grummes.
55
56
57
58
59
60

References

- 1
2
3
4
5
6
7
8
9 Agbandje M, Parrish CR, Rossmann MG. 1995. The Structure of Parvoviruses. *Seminars in Virology*.
10 6:299-309.
- 11
12 Arista S, De Grazia S, Di Marco V, Di Stefano R, Craxi A. 2003. Parvovirus B19 and 'cryptogenic' chronic
13 hepatitis. *J Hepatol*. 38:375-376.
- 14
15 Bernuau J, Durand F, Valla D. 1999. Parvovirus B19 infection and fulminant hepatitis. *Lancet*. 353:754-
16 755.
- 17
18 Bizjak G, Blondin D, Hammer R, Kozlowski P, Siegmann HJ, Stressig R. 2009. Acute infection with
19 parvovirus B19 in early pregnancy. *Ultrasound in Obstetrics & Gynecology*. 34:234-235.
- 20
21 Booth C, Inusa B, Obaro SK. 2010. Infection in sickle cell disease: A review. *Inter J Infect Diseases*. 14:E2-
22 E12.
- 23
24
25 Brown CS, Vanlent JWM, Vlcek JM, Spaan WJM. 1991. Assembly of Empty Capsids by Using Baculovirus
26 Recombinants Expressing Human Parvovirus-B19V Structural Proteins. *J Virol*. 65:2702-2706.
- 27
28 Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R. 2003. Fatal parvovirus B19V-
29 associated myocarditis clinically mimicking ischemic heart disease: An endothelial cell-mediated
30 disease. *Human Pathology*. 34:92-95.
- 31
32
33 Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F. 2009. Seroprevalence of parvovirus B19
34 in fibromyalgia syndrome. *Clinical Rheumatology*. 28:305-309.
- 35
36 Cassinotti P, Siegl C, Michel B, Bruhlmann P. 1998. Presence and significance of human parvovirus B19
37 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. *J*
38 *Med Virol*. 56:199-204.
- 39
40
41 Cotmore SF, Mckie VC, Anderson LJ, Astell CR, Tattersall P. 1986. Identification of the Major Structural
42 and Nonstructural Proteins Encoded by Human Parvovirus-B19V and Mapping of Their Genes by
43 Prokaryotic Expression of Isolated Genomic Fragments. *J Virol*. 60:548-557.
- 44
45 Drago F, Semino M, Rampini P, Rebora A. 1999. Parvovirus B19 infection associated with acute hepatitis
46 and a purpuric exanthem. *British J Dermatol*. 141:160-161.
- 47
48 Grossebley A, Eishubinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE. 1994.
49 Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of Hemophiliacs.
50 *Thrombosis and Haemostasis*. 72:503-507.
- 51
52
53 Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, Ferreira M, Araujo F. 2005. Prevalence of
54 parvovirus B19 and hepatitis a virus in Portuguese blood donors. *Transfusion and Apheresis*
55 *Science*. 33:305-309.
- 56
57
58
59
60

- 1
2
3 Hillingso JG, Jensen IP, Tom-Petersen L. 1998. Parvovirus B19 and acute hepatitis in adults. *Lancet*.
4 351:955-956.
5
6
7 Hsu TC, Chen TY, Lin MC, Tzang BS, Tsay GJ. 2005. Human parvovirus B19 infection in patients with
8 chronic hepatitis B or hepatitis C infection. *J Gastroenterol Hepatol*. 20:733-738.
9
10 Hubschen JM, Mihneva Z, Mentis AF, Schneider F, Aboudy Y, Grossman Z, Rudich H, Kasymbekova K,
11 Sarv I, Nedeljkovic J, Tahita M C, Tarnagda Z, Ouedraogo JB, Gerasimova AG, Moskaleva TN,
12 Tikhonova NT, Chitadze N, Forbi JC, Faneye AO, Otegbayo JA, Charpentier E, Muller CP. 2009.
13 Phylogenetic Analysis of Human Parvovirus B19 Sequences from Eleven Different Countries
14 Confirms the Predominance of Genotype 1 and Suggests the Spread of Genotype 3b. *J Clin*
15 *Microbiol*. 47:3735-3738.
16
17
18 Imarengiaye CO, Enosolease ME, Iribhogbe PE, Ehigiegba AE. 2006. Risk of transfusion-transmitted
19 hepatitis C virus in a tertiary hospital in Nigeria. *Public Health*. 120:274-278.
20
21 Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ. 1999. Human parvovirus B19 infection in acute
22 fulminant liver failure. *Archives of Virology*. 144:1713-1724.
23
24 Langnas AN, Markin RS, Cattral MS, Naides SJ. 1995. Parvovirus B19 as a possible causative agent of
25 fulminant liver failure and associated aplastic anemia. *Hepatology*. 22:1661-1665.
26
27
28 Lee PC, Hung CJ, Lin YJ, Wang JR, Jan MS, Lei HY. 2002 . A role for chronic parvovirus B19 infection in
29 liver dysfunction in renal transplant recipients? *Transplantation*. 73:1635-1639.
30
31 Mabayoje VO, Oparinde DP, Akanni EO, Taiwo SS, Muhibi MA, Adebayo T. 2007. Seroprevalence of
32 hepatitis B and C and of human immunodeficiency virus among blood donors in south-west
33 Nigeria. *British J Biomedical Science*. 64:177-179.
34
35
36 Nishida Y, Arai M, Yamamoto Y, Fukutake K. 1997. Serological and virological markers of human
37 parvovirus B19 infection in patients with haemophilia. *Haemophilia*. 3:137-142.
38
39 Opaleye OO, Zakariyahu TO, Tijani BA, and Bakarey AS. 2010. HBV, HCV co-infection among blood
40 donors in Nigeria. *Indian J.Pathol.Microbiol*. 53:182-183.
41
42
43 Schneider B, Fryer JF, Reber U, Fischer HP, Tolba RH, Baylis SA, Eis-Hubinger AM. 2008. Persistence of
44 novel human parvovirus PARV4 in liver tissue of adults. *Journal of Medical Virology*. 80:345-351.
45
46 Servant-Delmas A, Laperche S, Mercier M, Lefrere JJ. 2009a. Genetic diversity of human Erythroviruses.
47 *Pathologie Biologie*. 57:167-174.
48
49 Servant-Delmas A, Mercier M, Laperche S, Lefrere JJ. 2009b. Genetic diversity of human erythroviruses.
50 Consequences on infectious safety of plasma derivatives. *Transfusion Clinique et Biologique*.
51 16:482-488.
52
53 Soderlund M, vonEssen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. 1997. Persistence of
54 parvovirus B19 DNA in synovial membranes of young patients with and without chronic
55 arthropathy. *Lancet*. 349:1063-1065.
56
57
58
59
60

- 1
2
3 Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular evolutionary genetics analysis (MEGA)
4 software version 4.0. *Molecular Biology and Evolution*. 24:1596-1599.
5
6
7 Thompson JD, Higgins DG, Gibson TJ. 1994. Clustal-W - Improving the Sensitivity of Progressive Multiple
8 Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight
9 Matrix Choice. *Nucleic Acids Research*. 22:4673-4680.
10
11 Toan NL, Duechting A, Kreamsner PG, Song LH, Ebinger M, Aberle S, Binh VQ, Duy DN, Torresi J, Kandolf R,
12 Bock CT. 2006a. Phylogenetic analysis of human parvovirus B19V, indicating two subgroups of
13 genotype 1 in Vietnamese patients. *Journal of General Virology*. 87:2941-2949.
14
15 Toan NL, Song LH, Kreamsner PG, Duy DN, Binh VQ, Duechting A, Kaiser H, Torresi J, Kandolf R, Bock CT.
16 2006b. Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus
17 infection. *Journal of Hepatology*. 45:361-369.
18
19
20 Unek e CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. 2005. Prevalence of hepatitis-B
21 surface antigen among blood donors and human immunodeficiency virus-infected patients in
22 Jos, Nigeria. *Memorias do Instituto Oswaldo Cruz*. 100:13-16.
23
24
25 Wong S, Young NS, Brown KE. 2003. Prevalence of parvovirus B19 in liver tissue: No association with
26 fulminant hepatitis or hepatitis-associated aplastic anemia. *J Infect Diseases*. 187:1581-1586.
27
28 Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S. 1996. Human parvovirus B19 infection associated with
29 acute hepatitis. *Lancet*. 347:868-869.
30
31 Young NS, Brown KE. 2004. Mechanisms of disease - Parvovirus B19V. *N Engl J Med*. 350:586-597.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60